Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with GIFOX in Untreated NK/T Cell Lymphoma
NCT02808091Phase 2Terminated
- Sponsor
- National Cancer Centre Singapore
- Start
- Mar 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by National Cancer Centre Singapore. Started Mar 2011; status: terminated.
02
Drugs
bortezomib
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02808091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808091.